An interventional study of Smartphone Application for Post-Discharge Symptom Monitoring in Acute Disease, Acute Hospitalization and Coughing, sponsored by Mobile Health AG. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by Mobile Health AG · Not applicable, Interventional, and Health services research
The goal of this clinical trial is to evaluate whether the use of the medidux™ smartphone app can optimize post-discharge management for patients admitted to Acute Admission Units (AAU) with non-urgent health complaints. This trial includes adult patients (age ≥ 18) in Emergency Severity Index (ESI) triage system groups 4 (standard) or 5 (non-urgent), presenting with primary symptoms such as cough, back pain, or abdominal discomfort.
The main question it aims to answer is:
Can the medidux™ app reduce the incidence of AAU readmissions, emergency hospitalizations, or consultations with other medical providers within 7 days after initial admission?
Researchers will compare participants using the medidux™ app (intervention arm) with those receiving standard care (control arm) to observe potential differences in the rates of readmissions, emergency hospitalizations, and medical consultations.
Participants will:
57 studies on the registry are indexed under Acute Disease; 12 are open to participants now.
This study's planned enrollment of 417 is above the median of 192 across 33 interventional studies indexed under Acute Disease.
Browse Acute Disease studies →This is the only study on the registry with Mobile Health AG as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will use the medidux™ smartphone application to monitor their symptoms and vital signs for 7 days following discharge from the Acute Admission Unit (AAU). The app provides health monitoring features, prompts for symptom tracking, and guidance on whether further medical consultation is required. Participants will log daily health data and receive automated reminders. The app aims to reduce post-discharge readmissions and emergency hospitalizations by providing real-time support. Follow-up assessments will be conducted at day 7 and day 28 post-discharge to evaluate symptom progression and healthcare utilization.
Device: Smartphone Application for Post-Discharge Symptom Monitoring
Participants in this arm will receive standard post-discharge care as currently practiced in the Acute Admission Unit (AAU). This may include follow-up calls or appointments with healthcare providers to monitor symptoms and progression after discharge, but participants will not use the medidux™ app for symptom tracking or monitoring. Follow-up assessments will be conducted at day 7 and day 28 post-discharge to evaluate symptom progression and healthcare utilization.
This intervention involves the use of a smartphone application designed for symptom monitoring. The app enables participants to log daily health data, including symptoms and vital signs, for 7 days following discharge. It provides automated prompts and guidance for self-management, including when to seek medical assistance. The app does not provide direct medical intervention but facilitates remote symptom tracking to reduce readmissions and emergency hospitalizations. Follow-up consultations are conducted at day 7 and day 28.
Incidence of AAU Readmissions, Emergency Hospitalizations, and Consultations of Other Medical Providers within 7 (± 1) days
This measure evaluates the number of participants who experience at least one AAU readmission, emergency hospitalization, or consultation with other medical providers within 7 days of the initial AAU admission. This is a binary measure (yes/no) indicating whether such an event has occurred.
Time frame: 7 (± 1) days after the initial AAU admission
Incidence of AAU Readmissions, Emergency Hospitalizations, and Consultations of Other Medical Providers within 28 (± 1) days.
This measure captures the number of participants who experience at least one AAU readmission, emergency hospitalization, or consultation with other medical providers within 28 days of the initial AAU admission. This is a binary measure.
Time frame: 28 (± 1) days after the initial AAU admission
Incidence of AAU Readmissions within 7 (± 1) days
The number of participants who experience at least one readmission to the AAU within 7 days of their initial admission. This measure is a binary variable indicating whether a readmission has occurred.
Time frame: 7 (± 1) days after the initial AAU admission
Incidence of AAU Readmissions within 28 (± 1) days
The number of participants who experience at least one readmission to the AAU within 28 days of their initial admission. This is a binary variable indicating whether a readmission occurred.
Time frame: 28 (± 1) days after the initial AAU admission
Incidence of Emergency Hospitalizations within 7 (± 1) days
The number of participants who experience at least one emergency hospitalization within 7 days of their initial AAU admission. This is a binary variable indicating whether such an event occurred.
Time frame: 7 (± 1) days after the initial AAU admission
Incidence of Emergency Hospitalizations within 28 (± 1) days
The number of participants who experience at least one emergency hospitalization within 28 days of their initial AAU admission. This measure is a binary variable.
Time frame: 28 (± 1) days after the initial AAU admission
Incidence of Consultations of Other Medical Providers within 7 (± 1) days
This measure tracks the number of participants who consult with medical providers (outside of AAU or emergency hospitalizations) within 7 days of their initial AAU admission. It is a binary measure.
Time frame: 7 (± 1) days after the initial AAU admission
Incidence of Consultations of Other Medical Providers within 28 (± 1) days
This measure captures the number of participants who consult with medical providers within 28 days after their initial AAU admission. This is a binary variable.
Time frame: 28 (± 1) days after the initial AAU admission
Agreement Between ePRO-Derived AE Severity Index and Physician-Assessed AE Severity
This outcome assesses the agreement between the participant-reported ePRO-derived AE severity index (where 0.1 represents the least severe symptoms and 10 represents the most severe) and the AE severity index assessed by the investigator for one randomly selected symptom. The investigator uses a similar scale ranging from 0 (no symptoms) to 4 (severe symptoms). Agreement between the two assessments is calculated as a correlation coefficient.
Time frame: 7 (± 1) days after the initial AAU admission
Differences Between ePRO-Derived AE Severity and Physician-Assessed AE Severity Ratings
This outcome compares the differences between the participant-reported ePRO-derived AE severity index (ranging from 0.1 to 10, where higher scores represent more severe symptoms) and the investigator-assessed AE severity index (where 0 is no symptoms and 4 is severe symptoms) for a randomly selected symptom. The differences are presented in a cross-frequency table, showing any significant divergence between participant and physician assessments.
Time frame: 7 (± 1) days after the initial AAU admission
Number of Participant-Reported Symptoms by Severity
This outcome counts the number of participant-reported symptoms as assessed through the ePRO-derived AE severity index, which ranges from 0.1 (least severe) to 10 (most severe). Scores are linearly transformed into an index from 0 to 4, where 0 represents no symptoms and 4 represents severe symptoms.
Time frame: Daily over the 7 (± 1) day observation period
Evolution of Participant-Reported Symptoms Over Time
This outcome tracks the progression of participant-reported lead symptoms over time, using the ePRO-derived AE severity index (0.1 to 10 scale, where 0.1 indicates least severity and 10 indicates most severity). The symptoms are reported daily, and the index is transformed linearly into an index from 0 (no symptoms) to 4 (severe symptoms).
Time frame: Daily over the 7 (± 1) day observation period
Participant-Assessed Usability and Usefulness of the Smartphone App
Usability and usefulness of the app will be assessed based on participant responses to an 11-point Likert scale questionnaire. Participants will rate usability and usefulness across several domains, with scores ranging from 0 (does not apply) to 10 (fully applies), where 0 represents the worst outcome and 10 represents the best possible outcome for each item, such as ease of use, helpfulness in symptom management, and perceived impact on physician consultations.
Time frame: Day 7 (± 1) after the initial AAU admission
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.